Servier Announces Positive Topline Data from the Global Phase ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PARIS and BOSTON, Aug. 2, 2021 /PRNewswire-AsiaNet/ -- - TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. - Safety profile consistent with previously published data in patients with ...
Authors: LATEST ASIANET NEWS RELEASES